Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: US FTC takes action on Amgen’s Horizon deal; Hassan and Jimenez share their CEO experiences; Novartis lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 19 May 2023, including: US FTC takes action on Amgen, Inc.’s Horizon Therapeutics plc deal; Hassan and Jimenez share their CEO experiences; Novartis AG lays out Cosentyx plans; generally strong fiscal year for Japan’s pharma firms; and new Tagrisso data lift AstraZeneca PLC.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices" - Scrip, 16 May, 2023.)
(Also see "The Benefit Of Hindsight: Strategic Leadership Lessons From Pharma’s Past CEOs" - Scrip, 16 May, 2023.)
(Also see "Novartis Committed To Carving Out More Indications For Cosentyx" - Scrip, 12 May, 2023.)
(Also see "Japan Results Round-Up: Astellas, Daiichi Sankyo, Chugai Solid, Shionogi Hits New Heights" - Scrip, 16 May, 2023.)
(Also see "AstraZeneca Lifted By Tagrisso Combo Lung Cancer Data" - Scrip, 17 May, 2023.)